Table 1 Baseline demographics and clinical characteristics for the pneumococcal vaccination population
Characteristic | Pneumococcal vaccine population (N = 125) |
|---|---|
Age | |
 Mean (SD), years | 45.7 (13.8) |
Sex | |
 Women, n (%) | 107 (85.6) |
 Men, n (%) | 18 (14.4) |
Race | |
 White, n (%) | 124 (99.2) |
 Black/African American, n (%) | 1 (0.8) |
Region | |
 South America, n (%) | 105 (84.0) |
 North America, n (%) | 20 (16.0) |
Weight | |
 Mean (SD), kg | 68.9 (17.9) |
Duration of abatacept exposure during main study | |
 Mean (SD), months | 26.4 (2.5) |
Tender joint count/28 | |
 Mean (SD) | 20.4 (16.7) |
Swollen joint count/28 | |
 Mean (SD) | 13.9 (11.5) |
Patient pain | |
 100-mm VAS, mean (SD) | 51.0 (29.4) |
HAQ-DI | |
 Mean (SD) | 1.4 (0.8) |
C-reactive protein | |
 Mean (SD), mg/dL | 1.8 (2.5) |
Patient global assessment | |
 100-mm VAS, mean (SD) | 43.9 (31.9) |
Physician global assessment | |
 100-mm VAS, mean (SD) | 48.5 (26.3) |
DAS28 (C-reactive protein) | |
 Mean (SD) | 5.0 (1.9) |
Concomitant methotrexate | |
  n (%) | 115 (92.0) |